Non-small Cell Lung Cancer research hub
50 indexed studies · 23 currently recruiting
- recruitingPHASE1, PHASE2
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
This study is testing new combination medicines, BNT326 and BNT327, for people with advanced non-small cell lung cancer. It aims to find a safe dose and see how well they work, both for those who've had previous treatments and those who haven't.
United States · Australia · China - active not recruitingPHASE3
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
This study looks at a drug called osimertinib for people with a certain type of early-stage lung cancer after surgery. We want to see if it helps prevent the cancer from coming back compared to a dummy drug (placebo).
United States · Argentina · Brazil - recruitingPHASE4
Dabrafenib and/or Trametinib Rollover Study
This study allows patients already on dabrafenib and/or trametinib for certain cancers to continue treatment if their doctor thinks it's helping and they meet specific criteria. It's for people already in another study.
United States · Argentina · Austria - active not recruitingPHASE2
Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)
This study is for people with certain types of non-small cell lung cancer. It tests a new approach using a drug called durvalumab with chemotherapy, followed by either surgery or other treatments. The aim is to see how well it works and if it's safe.
United States · Austria · Canada - recruitingPHASE1, PHASE2
Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma and NSCLC
This study looks at combining two drugs, bexmarilimab and nivolumab, for advanced skin and lung cancers. It aims to find a safe dose and see if this combination can help when previous immunotherapy stopped working.
United Kingdom - active not recruitingPHASE1
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study is testing a new cell therapy for certain cancers that have a specific protein. It aims to see if it's safe and how well people tolerate it. The therapy uses your own modified cells to fight the cancer. Some participants will also receive a small amount of radiation.
United States · Canada - active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
United States · Australia · Belgium - active not recruitingPHASE3
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
This study is looking at a new drug called MEDI4736 for people who have had surgery for a certain type of lung cancer. Researchers want to see if this new drug works better than no further treatment to help stop the cancer from coming back.
United States · Australia · Brazil - active not recruiting
Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer
This study compares surgery with a special type of radiation (SBRT) for early-stage lung cancer. Doctors want to see which treatment works best and how it affects patients' daily lives over time. It's for people aged 18 and over in the UK.
United States · Canada - active not recruitingPHASE1, PHASE2
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
This study is looking at new drug combinations for a type of lung cancer called NSCLC with a specific genetic change (KRAS G12C). It checks how safe and effective these combinations are, including if a patient has taken similar drugs before or not.
United States · Belgium · France - recruitingPHASE2
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
This study looks at a new combination of medicines, IPH5201 and durvalumab, along with standard chemotherapy, for people with early-stage lung cancer. Doctors want to see if this new treatment, given before and after surgery, is safe and effective in helping to treat the cancer.
United States · France · Greece - recruitingPHASE3
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
This study is for people with early-stage lung cancer (NSCLC) that's been removed by surgery but has a high chance of coming back. Researchers want to see if new medicines, Intismeran and Pembrolizumab, can help stop the cancer from returning, compared to a dummy drug.
United States · Australia · Canada - active not recruitingPHASE2
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
This study looks at new treatments (nivolumab, sometimes with ipilimumab, or nivolumab with chemotherapy) for people with a certain type of lung cancer before surgery. It aims to see if these treatments are safe and how well they work to fight the cancer earlier.
United States · Canada - active not recruitingPHASE2
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy
This study looks at new ways to treat advanced non-small cell lung cancer that has grown despite previous treatments. It compares two different drug combinations, one with an extra anti-cancer medicine called atezolizumab, to see if they can help patients live longer without their cancer getting worse.
France - recruitingPHASE2
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
This study is testing a new drug, pumitamig, with chemotherapy (docetaxel) for advanced non-small cell lung cancer that has worsened after previous treatment. It aims to check the safety and how well the combination works.
United States · Australia · South Korea - recruitingNA
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
This study looks at how non-small cell lung cancer with a specific ALK gene change behaves when treated with new medicines. Researchers will study tissue and blood samples to understand the cancer better and help improve future treatments.
France - recruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
United States · Argentina · Australia - authorisedHuman Pharmacology (Phase I)- First administration to humans
Phase I clinical trial evaluating TG4070 in patients with non-small cell lung cancer
This early study is looking at a new medicine called TG4070 for people with a type of lung cancer called non-small cell lung cancer. It's the first time this medicine is being given to humans, to check if it's safe and how it works in the body.
France - recruiting
Observational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung Cancer
This study looks at how well a treatment combining chemotherapy and amivantamab works for advanced lung cancer with specific gene changes. It helps us understand real-life results and safety for people already receiving this treatment through early access programs.
France - active not recruitingPHASE2
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
This study is testing a new drug, taletrectinib, for people with a specific type of lung cancer called ROS1-positive non-small cell lung cancer. Researchers want to see how safe and effective this medication is. It's for patients whose cancer has spread or is difficult to treat.
United States · Canada · China - active not recruitingPHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations to treat advanced lung cancer. It compares two different drug mixes, each including chemotherapy, to see which works best and is safest for people with Stage IV or recurrent non-small cell lung cancer.
United States · Argentina · Australia - not yet recruitingPHASE1
Pulse Radiotherapy to Overcome Metastatic Immune System Evasion in Lung Cancer
This study looks at a new way to treat advanced lung cancer using special radiation alongside existing immunotherapy. It aims to see if this combination is safe and helps patients whose cancer has grown despite previous treatments.
Canada - active not recruitingNA
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
This study looks into whether extra chemotherapy after surgery helps people with early-stage non-small cell lung cancer that is considered high risk. It uses a special gene test to identify these patients and compares two ways of looking after them.
United States · France · Germany - recruitingPHASE1, PHASE2
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
This study is testing a new drug, BMS-986340, by itself and with other treatments for different advanced cancers. Researchers want to find the safest dose and see how well it works. This is the first time BMS-986340 has been tried in people.
United States · Australia · Canada - active not recruitingPHASE1
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
This study, called MTAPESTRY 104, is testing a new drug called Anvumetostat, alone or with other treatments, for advanced lung cancers that have a specific genetic change (MTAP-deletion). It aims to find the safest and most effective dose.
United States · Argentina · Australia - active not recruitingPHASE1
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
This study looks at a new combination of medicines, abemaciclib and pembrolizumab, for people with advanced non-small cell lung cancer or a specific type of breast cancer. It aims to see how safe and effective these treatments are together.
United States · Belgium · France - recruitingPHASE3
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
This study aims to see if a special ultrasound device, Exablate, can help standard cancer medicines work better for people with lung cancer that has spread to the brain. Researchers will compare this new approach to standard care alone.
United States · Canada · South Korea - active not recruitingPHASE1, PHASE2
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This study is testing a new discovery drug called RO7247669 for advanced cancers. It aims to find the safest and most effective dose, and see if it can shrink certain tumours like melanoma, lung, and oesophageal cancer. The drug works by boosting the body's own immune system to fight cancer.
Denmark · Georgia · Israel - recruitingPHASE1, PHASE2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
This study is testing a new drug, rezatapopt, for advanced cancers with a specific gene change (TP53 Y220C). It's also looking at rezatapopt with another drug, pembrolizumab, to see how safe and effective they are. It’s for people who have already had cancer treatment.
United States · Australia · France - recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study looks at new drug combinations for a specific type of advanced lung cancer. It compares a new drug, Divarasib, with Pembrolizumab, against standard treatments to see which works best and is safest for patients with KRAS G12C-mutated non-small cell lung cancer.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
This study is for people with a type of advanced lung cancer where standard treatments haven't worked or aren't suitable. It's testing a new drug, STX-721/PFL-721, to see how safe it is and if it can help by targeting specific changes in cancer cells.
United States · France · Germany - recruitingNA
Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
This study is looking at how a natural substance called Urolithin A might help the immune system of people with certain cancers who are having a type of treatment called immune checkpoint inhibitors. Some get Urolithin A, others get a dummy pill.
Germany - active not recruitingNA
Pulmonary Magnetic Resonance-guided Online Adaptive Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer
This study looks at a new type of radiation treatment for locally advanced non-small cell lung cancer. It uses MRI scans to guide the radiation, hoping to make treatment more precise, reduce side effects, and improve cancer control. This is a first step to see if this method works well.
Germany - active not recruitingPHASE1, PHASE2
Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC
This study is testing a new cancer vaccine, PDC*lung01, for people with a type of lung cancer called Non Small Cell Lung Cancer. It’s looking at how safe it is, how the body reacts to it, and if it helps treat the cancer, sometimes alongside other proven medicines.
Belgium · France · Germany - recruitingPHASE2
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
This study looks at combining two treatments — immunotherapy and a special type of radiotherapy called carbon ion therapy — for certain cancers that haven't worsened with current immunotherapy. It aims to see if this combination is safe and effective.
Germany · Italy - not yet recruitingNA
Radiation-induced Toxicity of the Heart
This study looks at how radiotherapy for certain cancers in the chest can affect the heart later on. Researchers are looking for warning signs, like from scans or blood tests, to help predict and prevent heart problems in patients.
Germany - recruitingPHASE2
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
This study looks at new ways to treat early-stage lung cancer. We want to see if adding an extra treatment to cemiplimab and chemotherapy works better before surgery. It's for adults whose lung cancer can be removed by an operation.
United States · Brazil · France - recruiting
PEMBRO-K : Evaluation of Pembrolizumab Therapeutic Pharmacological Monitoring Benefit in NSCLC
This study is looking at an existing lung cancer drug called pembrolizumab. We want to see how the amount of the drug in a patient's body connects to how well it works and if they have side effects, especially for non-small cell lung cancer.
France - active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer
This study looks at a medicine called abemaciclib for people in the UK with a certain type of advanced lung cancer (non-small cell lung cancer) that has a specific gene change (KRAS mutation) and has come back after other treatments. It aims to see how safe and effective abemaciclib is.
United States · Argentina · Austria - recruiting
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
This study looks at how a medicine called cemiplimab (Libtayo®) works for adults with advanced non-small cell lung cancer in everyday healthcare. Researchers want to understand its benefits and safety in real-world use.
Austria · France · Germany - ongoing, recruitingTherapeutic confirmatory (Phase III)
A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer
This study is looking at a new medicine called GME751 for advanced lung cancer that hasn't been treated before. It's comparing GME751 with a common cancer drug, Keytruda, to see which works best and if it's safe. It's for adults with non-small cell lung cancer.
Spain · Romania · Germany - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An open-label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neoantigen reactive T cells in patients with advanced non-small cell lung cancer
This study is looking at a new treatment for advanced lung cancer. It combines a special cell therapy (ATL001) with existing treatments like KEYTRUDA. The main goal is to check how safe these treatments are and if they help shrink tumours. It's for adults with non-small cell lung cancer.
Spain · Germany · France - active not recruiting
A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice
This study looks at how a cancer drug called atezolizumab works in real patients. Researchers want to see its effects and safety under normal hospital care, for different types of cancer it's approved for.
Argentina · Austria · Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1b Study of Dato-DXd in Combination with Pembrolizumab with or without Platinum Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer
This study is looking at a new combination of medicines for people with advanced lung cancer. It combines an experimental drug, Dato-DXd, with pembrolizumab, a common cancer medicine, sometimes also with chemotherapy. It's an early-stage study to see if it's safe and how it works.
Spain · Italy - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with non-small-cell lung cancer (NSCLC)
This study is testing a new cancer 'vaccine' called PDC*lung01 for non-small-cell lung cancer. It checks if it's safe, how well people can tolerate it, and if it helps fight the cancer, sometimes with another drug called anti-PD-1.
France · Germany · Netherlands - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - recruitingPHASE3
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
This study looks at a new drug, gotistobart, for advanced non-small cell lung cancer that has worsened after previous PD-1/PD-L1 treatment. It compares gotistobart to standard chemotherapy (docetaxel) to see if it can help people live longer.
United States · Australia · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
Precision Immuno-Oncology for advanced Non-small cell lung cancer patients with PD-1 ICI Resistance (PIONeeR clinical study)
This study is for adults with a type of advanced lung cancer (non-small cell lung cancer) that has stopped responding to previous immune-boosting treatments. It's testing new combinations of medicines to see if they can help control the cancer, looking at how many people's cancer stops growing or shrinks after 12 weeks.
France - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Global, Randomized, Phase 3, Open-Label Study of REGN2810 (Anti-PD-1 Antibody) versus Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic PD-L1 + Non-Small Cell Lung Cancer
This study looks at a new drug (REGN2810) compared to standard chemotherapy for advanced non-small cell lung cancer. It aims to see if the new drug helps people live longer and stops cancer from growing, especially for those whose cancer has a specific protein called PD-L1.
Czechia · Poland · Greece - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Two-Part Randomized, Phase 3 Study of Combinations of Cemiplimab (Anti- PD-1 Antibody) and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of anti-cancer medicines for people with advanced non-small cell lung cancer. It aims to see if these new approaches can help people live longer and improve their quality of life, compared to standard treatments.
France · Poland · Ireland